The epidemiology of myasthenia gravis. 2021

Ana-Maria Bubuioc, and Aigerim Kudebayeva, and Saule Turuspekova, and Vitalie Lisnic, and Maurizio Angelo Leone
Department of Neurology, Nicolae Testemitanu State University of Medicine and Pharmacy Chisinau, the Republic of Moldova.

Neuromuscular junction (NMJ) disorders include several dysfunctions that ultimately lead to muscle weakness. Myasthenia gravis (MG) is the most prevalent NMJ disorder with a highly polymorphic clinical presentation and many different faces. Being an autoimmune disease, MG correlates with the presence of detectable antibodies directed against the acetylcholine receptor, muscle-specific kinase, lipoprotein-related protein 4, agrin, titin, and ryanodine in the postsynaptic membrane at the NMJ. MG has become a prototype serving to understand both autoimmunity and the function of the NMJ better. The aim of this review is to synthesize some of the epidemiological data available. Epidemiological data regarding MG are important for postulating hypotheses regarding its etiology and facilitating the description of MG subtypes. Thus, adequate documentation through broad databases is essential. The incidence and prevalence of MG reported around the globe have been rising steadily and consistently over the past decades. Ethnic aspects, gender-related differences, and environmental risk factors have been described, implying that these might contribute to a specific phenotype, further suggesting that MG may be considered an umbrella term that covers several clinical entities.

UI MeSH Term Description Entries
D009157 Myasthenia Gravis A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. Anti-MuSK Myasthenia Gravis,MuSK MG,MuSK Myasthenia Gravis,Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Generalized,Myasthenia Gravis, Ocular,Anti MuSK Myasthenia Gravis,Generalized Myasthenia Gravis,Muscle Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Anti-MuSK,Myasthenia Gravis, MuSK,Ocular Myasthenia Gravis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D015994 Incidence The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases in the population at a given time. Attack Rate,Cumulative Incidence,Incidence Proportion,Incidence Rate,Person-time Rate,Secondary Attack Rate,Attack Rate, Secondary,Attack Rates,Cumulative Incidences,Incidence Proportions,Incidence Rates,Incidence, Cumulative,Incidences,Person time Rate,Person-time Rates,Proportion, Incidence,Rate, Attack,Rate, Incidence,Rate, Person-time,Rate, Secondary Attack,Secondary Attack Rates
D015995 Prevalence The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time. Period Prevalence,Point Prevalence,Period Prevalences,Point Prevalences,Prevalence, Period,Prevalence, Point,Prevalences
D020022 Genetic Predisposition to Disease A latent susceptibility to disease at the genetic level, which may be activated under certain conditions. Genetic Predisposition,Genetic Susceptibility,Predisposition, Genetic,Susceptibility, Genetic,Genetic Predispositions,Genetic Susceptibilities,Predispositions, Genetic,Susceptibilities, Genetic

Related Publications

Ana-Maria Bubuioc, and Aigerim Kudebayeva, and Saule Turuspekova, and Vitalie Lisnic, and Maurizio Angelo Leone
September 2003, Annals of the New York Academy of Sciences,
Ana-Maria Bubuioc, and Aigerim Kudebayeva, and Saule Turuspekova, and Vitalie Lisnic, and Maurizio Angelo Leone
March 2004, Seminars in neurology,
Ana-Maria Bubuioc, and Aigerim Kudebayeva, and Saule Turuspekova, and Vitalie Lisnic, and Maurizio Angelo Leone
May 1994, Neurologic clinics,
Ana-Maria Bubuioc, and Aigerim Kudebayeva, and Saule Turuspekova, and Vitalie Lisnic, and Maurizio Angelo Leone
January 2006, Srpski arhiv za celokupno lekarstvo,
Ana-Maria Bubuioc, and Aigerim Kudebayeva, and Saule Turuspekova, and Vitalie Lisnic, and Maurizio Angelo Leone
January 1987, Monographs in allergy,
Ana-Maria Bubuioc, and Aigerim Kudebayeva, and Saule Turuspekova, and Vitalie Lisnic, and Maurizio Angelo Leone
January 1978, Advances in neurology,
Ana-Maria Bubuioc, and Aigerim Kudebayeva, and Saule Turuspekova, and Vitalie Lisnic, and Maurizio Angelo Leone
September 2015, Nihon rinsho. Japanese journal of clinical medicine,
Ana-Maria Bubuioc, and Aigerim Kudebayeva, and Saule Turuspekova, and Vitalie Lisnic, and Maurizio Angelo Leone
March 2016, Yonsei medical journal,
Ana-Maria Bubuioc, and Aigerim Kudebayeva, and Saule Turuspekova, and Vitalie Lisnic, and Maurizio Angelo Leone
October 1984, Acta neurologica Scandinavica,
Ana-Maria Bubuioc, and Aigerim Kudebayeva, and Saule Turuspekova, and Vitalie Lisnic, and Maurizio Angelo Leone
January 1969, Journal of the neurological sciences,
Copied contents to your clipboard!